Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.

European Urology
Ronghao WangChawnshang Chang

Abstract

While androgen-deprivation-therapy with the recently developed antiandrogen enzalutamide (Enz) shows promising therapeutic benefits in men with metastatic castration-resistant prostate cancer (PCa), many patients develop resistance to Enz, which may involve the induction of the androgen receptor (AR) splicing variant 7 (AR-v7). Our aim is to identify the mechanisms responsible for AR-v7 production and to develop novel preclinical approaches to suppress the Enz-resistant (EnzR) PCa. We established EnzR-PCa cell lines and examined the long noncoding RNA Malat1 (Malat1) function in conferring Enz resistance. We also examined the in vivo effects of Malat1 short interfering RNA and the AR-v7 degradation enhancer, ASC-J9®. Enz resistance and expression of Malat1 and AR-v7. All statistical comparisons were analyzed with a t-test or one way analysis of variance followed by t-test. We demonstrated that Malat1 is indispensable for Enz-induced AR-v7 production in VCaP and EnzR-C4-2 cells. We observed increased AR-v7 and Malat1 expression in our established EnzR-PCa cell lines and in some PCa patients who received Enz treatment. Targeting the Malat1/AR-v7 axis resulted in altering the PCa resistance to androgen deprivation therapy with Enz...Continue Reading

Citations

Aug 23, 2018·Journal of Cellular Physiology·Li LeiQinghai Zeng
Jun 7, 2017·Nature Reviews. Urology·Louise Stone
Feb 9, 2018·Expert Opinion on Therapeutic Targets·Takuma UoCynthia C Sprenger
Oct 3, 2019·Expert Review of Molecular Diagnostics·Emmy BoerrigterJack A Schalken
Apr 3, 2019·Bone Research·Andreia Machado SilvaMaria Inês Almeida
Feb 28, 2018·Oncotarget·Huaqi WangGuoqiang Zhao
Jun 23, 2018·Oncology Letters·Qun RaoYuan Chen
Jul 1, 2020·Journal of Cellular and Molecular Medicine·Sheng-Lin GaoMin Tang
Aug 9, 2019·Journal of Experimental & Clinical Cancer Research : CR·Xiaoran LongWen Di
Dec 29, 2018·International Journal of Molecular Sciences·Tingjin ZhengRuian Xu
Dec 12, 2017·Protein Engineering, Design & Selection : PEDS·Nancy L GoicocheaMichael B Lilly
Jun 19, 2018·Frontiers in Oncology·Alexandra Vander ArkXiaohong Li
Mar 7, 2020·Prostate Cancer and Prostatic Diseases·Changxue LuJun Luo
Sep 11, 2020·Proceedings of the National Academy of Sciences of the United States of America·Wei LiuXuetao Cao
Jun 7, 2020·Non-coding RNA·Gayatri ArunDavid L Spector
Jun 14, 2019·Frontiers in Chemistry·Giovanni L Beretta, Nadia Zaffaroni
Jan 5, 2021·Journal of Experimental & Clinical Cancer Research : CR·Hao TianChawnshang Chang
Jan 12, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Bela GoyalSubash Chandra Gupta
Feb 19, 2019·Asian Journal of Urology·Cameron M Armstrong, Allen C Gao
Nov 1, 2020·Cells·Christian T StackhouseChristopher D Willey
Apr 17, 2021·Biochemical and Biophysical Research Communications·Xiwu OuyangYao Xiao

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.